The Swedish Competition Authority, as part of a second phase investigation, clears a merger between the only two companies selling the same active pharmaceutical ingredient in the OTC market in Sweden (GlaxoSmithKline Dungarvan /AstraZeneca Tika)

The parties to the transaction, i.e., GlaxoSmithKline Dungarvan ("GSK") and AstraZeneca Tika ("AZT") are active in Sweden within the field of, inter alia, consumer health. The Swedish Competition Authority ("SCA") divided the sale of pharmaceuticals into the following three markets; personal care, prescription and requisition. Both GSK and AZT are active within all three markets in Sweden. The markets for prescription and requisition of pharmaceuticals differ from the market for personal care because in the personal care market the customer has the possibility to choose which

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • Carlsberg (Copenhagen)

Citation

Hanna Danwall, The Swedish Competition Authority, as part of a second phase investigation, clears a merger between the only two companies selling the same active pharmaceutical ingredient in the OTC market in Sweden (GlaxoSmithKline Dungarvan /AstraZeneca Tika), 3 avril 2009, e-Competitions April 2009, Art. N° 27210

Visites 185

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues